Companies Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics CEO salary & total pay, FY2025: $713K
Brainstorm Cell Therapeutics (BCLI) CEO salary, fiscal 2025: Chaim Lebovits was paid a salary of $291,667 and $713,341 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Brainstorm Cell Therapeutics Inc’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Chaim Lebovits's complete compensation dossier
A PDF and a CSV sent to your email: Chaim Lebovits's pay in every fiscal year Brainstorm Cell Therapeutics Inc reported it, line by line, with Chaim Lebovits's equity grants and Brainstorm Cell Therapeutics Inc's disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $1,128,795FY2023
- $750,303FY2024
- $713,341FY2025
CEO total pay was $713,341 in fiscal 2025, down from $750,303 in fiscal 2024.
FY2025: salary $291,667 · bonus $0 · stock awards $256,800 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chaim Lebovits | $291,667 | $0 | $256,800 | $0 | $0 | $0 | $164,874 | $713,341 |
| Chief Executive Officer & President | ||||||||
| Uri Yablonka | 123,565 | 0 | 128,400 | 0 | 0 | 0 | 76,348 | 328,313 |
| Executive Vice President, Chief Business Officer, Secretary and Director | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Chaim Lebovits | $713,341 | $750,303 | $1,128,795 | ↓ −36,962 |
| Uri Yablonka | 328,313 | 266,138 | 247,055 | ↑ +62,175 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation structure for executives is primarily based on base salary and discretionary cash bonuses, with long-term incentives provided through stock options and restricted stock awards that vest over time to align executive interests with long-term shareholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | false |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Chaim Lebovits | RSU | — | 60,000 | — | $33,000 |
| Chaim Lebovits | RSU | — | 10,173 | — | 5,595 |
| Chaim Lebovits | RSU | — | 520 | — | 286 |
| Chaim Lebovits | RSU | — | 1,039 | — | 571 |
| Dagher | Option | 3,000 | 2,333 | 25.95 | — |
| Dagher | RSU | — | 7,258 | — | 3,992 |
| Dagher | RSU | — | 25,000 | — | 13,750 |
| Uri Yablonka | RSU | — | 40,000 | — | 22,000 |
| Uri Yablonka | RSU | — | 3,647 | — | 2,006 |
| Uri Yablonka | Option | 889 | — | 11.25 | — |
| Uri Yablonka | Option | 889 | — | 11.25 | — |
| Uri Yablonka | Option | 889 | — | 11.25 | — |
| Uri Yablonka | Option | 889 | — | 11.25 | — |
| Uri Yablonka | Option | 889 | — | 11.25 | — |
| Uri Yablonka | Option | 889 | — | 11.25 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dr. Jacob Frenkel | $0 | $85,600 | $0 | — | — | $85,600 |
| Dr. Irit ArbelIndependent · Audit · GNC (Chair) | 0 | 65,625 | 0 | — | — | 65,625 |
| Dr. Anthony PolverinoGNC | 0 | 51,360 | 0 | — | — | 51,360 |
| Dr. Menghisteab BairuIndependent · Audit | 0 | 51,360 | 0 | — | — | 51,360 |
| Nir NaorIndependent · Audit (Chair) · GNC | 0 | 0 | 0 | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $30,000 |
|---|---|
| Annual equity retainer | $444 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 222 / 222 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $0 |
| Equity awards (grant-date value) | $253,945 |
| All other compensation | $0 |
| Total cost of the board | $253,945 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Brainstorm Cell Therapeutics as a peer
Companies that benchmark against BCLI
No companies currently name BCLI as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Brainstorm Cell Therapeutics Inc | 2025 | Chaim Lebovits | $291,667 | $256,800 | $0 | $0 | $713,341 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-25 | — | — | — | — | — |
| 2024 | 2024-09-16 | 23,439,724 | 2,640,861 | 3,262,782 | 89.87% | Passed |
| 2023 | 2023-12-18 | — | — | — | — | — |
| 2021 | 2021-12-14 | 7,594,234 | 981,374 | 94,596 | 88.56% | Passed |
| 2020 | 2020-11-10 | — | — | — | — | — |
| 2019 | 2019-12-11 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-25 | —a |
| 2024 | 2024-09-16 | 89.87%b |
| 2023 | 2023-12-18 | —c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers (Proposal No. 7) The approval of Proposal No. 7 requires the affirmative vote of a majority of the votes cast by the stockholders present at the virtual Meeting or represented by proxy and entitled to vote on the matter. || Abstentions: Abstentions and broker non-votes will not be counted as votes cast or voted on Proposal No. 7.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dr. Jacob Frenkel | Director | 2026-07-24 | A | 100,000 | $0 | $0 | Common | Form 4 ↗ |
| Peter Joe Pitts | Director | 2026-07-24 | A | 900,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (15 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Chaim Lebovits. 10-K, filed 2026-03-31. Section “Executive Compensation”. As printed: 713,341. View filing ↗
- Section 01, Uri Yablonka. 10-K, filed 2026-03-31. Section “Executive Compensation”. As printed: 328,313. View filing ↗
- Section 08, Dr. Jacob Frenkel. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 85,600. View filing ↗
- Section 08, Dr. Irit Arbel. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 65,625. View filing ↗
- Section 08, Dr. Anthony Polverino. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 51,360. View filing ↗
- Section 08, Dr. Menghisteab Bairu. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 51,360. View filing ↗
- Section 08, Nir Naor. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: —. View filing ↗
- Section 02, Dr. Jacob Frenkel 2026-07-24. Form 4, filed 2026-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Joe Pitts 2026-07-24. Form 4, filed 2026-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-25. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-09-16. Item 5.07 · say-on-pay result. As reported: 89.87% (votes for as printed: 23,439,724). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-12-20. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 0 + equity 253,945 + all other 0 = 253,945, summed across the director compensation table rows.
- Brainstorm Cell Therapeutics Inc (subject), Section 10b CEO total. 10-K, filed 2026-03-31. CEO total compensation as printed in Brainstorm Cell Therapeutics Inc's own proxy. As printed: 713,341. View filing ↗